New checkpoint inhibitors are being tested across various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and head and neck squamous cell carcinoma. These trials aim to determine the effectiveness and safety of these new drugs in different cancer types and patient populations.
